Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients (0954A-322)
Phase 3
Completed
- Conditions
- Hypertension
- Registration Number
- NCT00398541
- Lead Sponsor
- Organon and Co
- Brief Summary
Evaluate the antihypertensive and neuroprotective effects of Hyzaar(R) in elderly subjects in comparison with Natrilix(TM).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 41
Inclusion Criteria
- ACEi or ARB naive or not taking ACEi or ARB concurrently for at least one month before the run-in period
- Be able to carry out his or her own daily activity
-
- Be at least 50 years old at inclusion in the study Be diagnosed with mild to moderate hypertension, treated or untreated
- Literate
- Not taking any cognitive-enhanced agent at baseline
- Present with a memory complain ( spontaneous or informed by caregiver)
Exclusion Criteria
- Congestive heart failure with NYHA class >2
- Renal failure or renal insufficiency with serum creatinine >1.4mg/dl
- chronic severe liver disease with abnormal GPT and GOT >2 times of upper normal limits
- Diagnosed with major depression when entering the study
- Foreign language as his or her mother tongue so that the test results will not be reliable
- History of stroke or transient ischemic attack (stroke is defined as focal neurological sign progressing stepwise)
- Hypersensitive to the active ingredient and any other component of losartan potassium and indapamide tablets
- Major hearing loss/deafness and/or major visual impairment/blindness preventing from performing the tests
- Myocardial infarction within the past 6 months
- Single functioning kidney
- Anuria
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Neuropsychological tests and blood pressure after treatment of 12 weeks after treatment of 12 weeks
- Secondary Outcome Measures
Name Time Method